Loading...
Previous studies have indicated an association between dexfenfluramine and valve regurgitation. However, the reported prevalence and severity of regurgitation vary significantly. This multicenter U.S. study attempted to determine the true prevalence of valve disease and other contributing factors in 172 dexfenfluramine patients compared with 172 unexposed matched controls and 68 unmatched subjects who met the entry criteria (51 treated with dexfenfluramine and 17 controls). Three echocardiographers independently interpreted each study participant's echocardiogram. Mean treatment duration for dexfenfluramine patients was 6.9 months, and mean interval between treatment discontinuation and echocardiogram was 8.5 months.
Dexfenfluramine-treated …